LenalidoMide (heMihydrate)
- CAS No.
- 847871-99-2
- Chemical Name:
- LenalidoMide (heMihydrate)
- Synonyms
- Lenalidonmide;CC-5013 hemihydrate;LenalidoMide (heMihydrate);Lenalidomide hemihydrate (Revlimid, CC 5013);3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione hemihydrate;2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, hydrate (2:1);IKZF3,inhibit,IKZF1,ligand,Inhibitor,CC-5013 hemihydrate,degradation,myeloma,Ligands for E3 Ligase,analog,multiple,Lenalidomide hemihydrate,immunomodulatory,E3 ligase-recruiting Moiety,CRL4,ligase,Molecular Glues,cereblon,Apoptosis
- CBNumber:
- CB22682011
- Molecular Formula:
- C26H28N6O7
- Molecular Weight:
- 536.53652
- MDL Number:
- MFCD28167742
- MOL File:
- 847871-99-2.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| storage temp. | Store at -20°C |
|---|---|
| solubility | DMSO : 50 mg/mL (186.38 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) |
| form | Powder |
| color | Off-white to pink |
| InChI | InChI=1S/2C13H13N3O3.H2O/c2*14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18;/h2*1-3,10H,4-6,14H2,(H,15,17,18);1H2 |
| InChIKey | OTJHSDXKMBRCMM-UHFFFAOYSA-N |
| FDA UNII | XQT0NAW8WD |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
LenalidoMide (heMihydrate) price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-2123 | Lenalidomide (hemihydrate) 99.98% | 847871-99-2 | 100mg | $65 | 2026-06-04 | Buy |
| ChemScene | CS-2123 | Lenalidomide (hemihydrate) 99.98% | 847871-99-2 | 500mg | $117 | 2026-06-04 | Buy |
| ChemScene | CS-2123 | Lenalidomide (hemihydrate) 99.98% | 847871-99-2 | 1g | $182 | 2026-06-04 | Buy |
| ApexBio Technology | B1188 | Lenalidomide hemihydrate | 847871-99-2 | 50mg | $55 | 2026-05-06 | Buy |
| ApexBio Technology | B1188 | Lenalidomide hemihydrate | 847871-99-2 | 100mg | $66 | 2026-05-06 | Buy |
LenalidoMide (heMihydrate) Chemical Properties,Uses,Production
Uses
Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
Biological Activity
LenalidoMide (heMihydrate) is a derivative of Thalidomide and an orally active immunomodulator. It is a ligand for the ubiquitin E3 ligase cereblon (CRBN), selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. It specifically inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and induces the release of interleukin-2 (IL-2) from T cells.
in vitro
LenalidoMide (heMihydrate) is potent in stimulating T cell proliferation and IFN-γ and IL-2 production. It has been shown to inhibit production of pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and elevate the production of anti-inflammatory cytokine IL-10 from human PBMCs. It downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction, which augments the apoptosis of myeloma cells. Dose-dependent interaction with the CRBN-DDB1 complex is observed with Thalidomide, Lenalidomide and Pomalidomide, with IC 50 values of ~30 μM, ~3 μM and ~3 μM, respectively, These reduced CRBN expression cells (U266-CRBN 60 and U266-CRBN 75 ) are less responsive than the parental cells to antiproliferative effects Lenalidomide across a dose-response range of 0.01 to 10 μM . Lenalidomide, a thalidomide analog, functions as a molecular glue between the human E3 ubiq uitin ligase cereblon and CKIα is shown to induce the ubiquitination and degradation of this kinase, thus presumably killing leukemic cells by p53 activation.
in vivo
The toxicity of LenalidoMide (heMihydrate) doses up to 15, 22.5, and 45 mg/kg via IV, IP, and PO routes of administration. Limited by solubility in our PBS dosing vehicle, these maximum achievable Lenalidomide doses are well tolerated with the exception of one mouse death (of four total dosed) at the 15 mg/kg IV dose. Notably, no other toxicities are observed in the study at IV doses of 15 mg/kg (n=3) or 10 mg/kg (n=45) or at any other dose level through IV, IP, and PO routes.
target
| Cereblon
|
IC 50
Cereblon
References
[1] Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309. DOI:10.1155/2013/208309
[2] Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25. DOI:10.1016/j.cell.2018.07.045
[3] Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36. DOI:10.1186/1756-8722-2-36
[4] Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. DOI:10.1038/leu.2012.119
[5] Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14(4):872-82. DOI:10.1208/s12248-012-9401-2
LenalidoMide (heMihydrate) Preparation Products And Raw materials
Raw materials
Preparation Products
LenalidoMide (heMihydrate) Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hunan Hui Bai Shi Biotechnology Co., Ltd. | 0731-85526065 13308475853 | ivy@hnhbsj.com | China | 7236 | 62 |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Haoyuan Chemexpress Co., Ltd. | 021-58950125 | info@chemexpress.com | China | 7545 | 61 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3493 | 58 |
| Guangzhou QiYun Biotechnology Co., Ltd. | 020-61288194 61288195 | 505721671@qq.com | China | 3853 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Amadis Chemical Company Limited | 571-89925085 | sales@amadischem.com | China | 131885 | 58 |
| Musechem | +1-800-259-7612 | info@musechem.com | United States | 4648 | 60 |
| Shanghai Zhen Li Biological Technology Co., Ltd | 021-16621358918; 18516310516;16621358918;13045646768 | zhenlipharma888@163.com | China | 19060 | 58 |
| Shandong Platinum Pharmaceutical Co., Ltd. | 0531-88963280 18396830603 | sales@boyuanpharm.com | China | 206 | 58 |
View Lastest Price from LenalidoMide (heMihydrate) manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Lenalidomide hemihydrate
847871-99-2
|
$29.00 | 96.22% | 10g | TargetMol Chemicals Inc. |
-
- Lenalidomide hemihydrate
847871-99-2
- $29.00
- 96.22%
- TargetMol Chemicals Inc.
